Treats Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy. ANDA 213936, held by Accord Healthcare. Methylphenidate Hydrochloride.
As of Nov 18, 2026, ANDA 213936 (Methylphenidate Hydrochloride), held by Accord Healthcare, was first approved by FDA on Oct 28, 2020, with 3 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults Narcolepsy Methylphenidate hydrochloride is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2020 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Sep 28, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 30, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 13, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 28, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters